The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®

NCT05373303 | Completed

• 1 other identifier: DW_EPO401
• Study Type: interventional
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

The study was conducted to evaluate whether the efficacy and safety profile of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.

Conditions

Chronic Kidney Disease (CKD)

Outcome Measures

Primary Outcomes (1)

• Hb level change

  Hb level change between Test and Reference Drug

  baseline (Week 5-8/9-12) and evaluation period (Week 33-36/37-40).

Secondary Outcomes (1)

• mean change in weekly dosage per kg body weight

  baseline (Week 5-8/9-12) and evaluation period (Week 33-36/37-40).

Other Outcomes (3)

• instability rate of Hb (hemoglobin)

  maintenance (week 10-14/32-36) and evaluation period (Week 33-36/37-40)

• Hb (hemoglobin) and hematocrit level

  maintenance (week 10-14/32-36) and evaluation period (Week 33-36/37-40)

• incidence of adverse event

  during the study evaluation from baseline (Week 5-8/9-12) to evaluation period (Week 33-36/37-40)

Study Arms (2)

Test Drug

EXPERIMENTAL

Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL

Biological: Recombinant Human Erythropoietin Alpha

Reference Drug

ACTIVE COMPARATOR

Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL

Biological: Recombinant Human Erythropoietin Alpha

Interventions

Recombinant Human Erythropoietin Alpha BIOLOGICAL

This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection

Test Drug

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients who are at least 18 years old and younger than 75 years of age at the time of screening visit.
• Patients with End-Stage Renal Failure (ESRD) who are chronically receiving hemodialysis and have anemia.
• Patients with a mean baseline Hb concentration within Hb level ≥ 9 g/dL during the screening period.
• Haemodialysis patients with anemia associated with Chronic Kidney Disease (CKD) currently receiving stable maintenance therapy with Epoetin alfa at least once per week
• Adequate iron substitution status (serum ferritin ≥ 100 μg /dl or saturated transferrin levels ≥ 20%).
• Patients who understand the information provided to them or their representatives and may provide written consent.

You may not qualify if:

• Contraindication with Epoetin therapy.
• Documented active bleeding in the last 12 weeks prior to screening period.
• Any blood transfusion within the last 2 weeks prior Screening period.
• History of malignancy of any organ system within the last 5 years.
• Patients with uncontrolled hypertension (in case the mean value of diastolic blood pressure as measured 4 times during the baseline observation period is 110 mmHg or more).
• Patients hyporesponsive epoetin treatment or had medical history of experiencing pure red blood cell forming failure after being administered with Epoetin products.
• Known bone marrow fibrosis (osteitis fibrosa cystica).
• Patient with serious cardiovascular disorders: myocardial infarction, patients with congestive heart failure (NYHA class Ⅲ or higher), ischemic vascular disease
• Patient received percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) during the last 6 months prior to screening.
• Patient with the following liver disorder: Patient diagnosed with liver cirrhosis, hepatitis B, or on active treatment hepatitis C, and patients with ALT or AST exceeding the upper limits of the normal level by more than double.
• Patients whose kidney transplant is expected or already planned for survival.
• Secondary anemia to other causes different to the CKD (aplastic anemia, hemolytic anemia, sickle cell anemia, multiple myeloma, leukemia, myelodysplastic syndrome).
• Patients with the following diseases and who are considered unfit to enroll in the clinical study: mental system disease, mental disease, drug intoxication, epilepsy, lung infarction, cerebral infarction, positive HIV antibody, systemic lupus erythematosus, immunosuppressive condition and general infection
• Pregnancy or lactation period in female patients, or women of childbearing potential without an effective method of birth control.
• Patients who were considered unfit for study by the principal investigators or by the co-investigator.

Sponsors & Collaborators

• PT. Daewoong Infion: lead
• Equilab International: collaborator

Study Sites (1)

Gatot Soebroto Army Hospital

Jakarta, 10410, Indonesia

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jonny Jonny, MD

  Gatot Soebroto Army Hospital, Jakarta

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: open-label, randomized, active drug-comparative, parallel-designed

Study Record Dates

• First Submitted: April 26, 2022
• First Posted: May 13, 2022
• Study Start: November 7, 2019
• Primary Completion: May 15, 2021
• Study Completion: January 28, 2022
• Last Updated: July 14, 2022

Record last verified: 2022-07

Locations

ID (1)